Benitec Biopharma Ltd (BLT):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C12400)
◆英語タイトル:Benitec Biopharma Ltd (BLT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12400
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年12月
◆ページ数:59
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥52,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥78,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Benitec Biopharma Ltd (Benitec) is a clinical stage biotechnology company. The company develops novel therapeutics for the treatment of chronic and life threatening diseases based on its proprietary gene silencing DNA directed RNA interference (ddRNAi) technology. It develops ddRNAi based therapeutics for various conditions such as hepatitis B, wet age-related macular degeneration and OPMD. The company also licenses ddRNAi to various biopharmaceutical companies for the development of drugs. The company has research laboratories in Hayward, California, the US. Benitec is headquartered in Sydney, New South Wales, Australia.

Benitec Biopharma Ltd (BLT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Benitec Biopharma Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Benitec Biopharma Acquires Rights to Hepbarna from Biomics 13
Partnerships 14
Axovant Sciences Enters into Research Partnership with Benitec Biopharma 14
Benitec Biopharma to Enter into Research Agreement with NantVentures 15
ReNeuron Enters into Research Agreement with Benitec Biopharma 16
Benitec Biopharma Enters Into An Agreement With Stanford University 17
Licensing Agreements 18
Axovant Sciences Enters into Licensing Agreement with Benitec Biopharma 18
Benitec Biopharma Enters into Licensing Agreement with Nant Capital 19
Benitec Biopharma Enters into Licensing Agreement with Asklepios BioPharma 20
Benitec Biopharma Enters into Option for License Agreement with Touchlight Genetics for doggybone DNA 21
Benitec Biopharma Enters into Licensing Agreement with Circuit Therapeutics 22
Benitec Biopharma Enters Into Licensing Agreement With Regen BioPharma For ddRNAi Gene Silencing Technology 23
Benitec Biopharma Enters Into Licenising Agreement With uniQure 25
Benitec Biopharma Enters Into Licensing Agreement With Genable Technologies 26
Benitec Enters Into Licensing Agreement With Calimmune For ddRNAi Technology 27
Benitec Biopharma Enters into Licensing Agreement with 4D Molecular Therapeutics 28
Benitec Biopharma Enters Into Licensing Agreement With University of New South Wales For Tribetarna 29
Equity Offering 30
Benitec Biopharma Raises USD4.7 Million in Rights Offering of Shares 30
Benitec Biopharma to Raise USD2 Million in Private Placement of American Depositary Shares 31
Benitec Biopharma Raises USD4.11 million in Private Placement of Shares 32
Benitec Biopharma Raises USD13.8 Million in Public Offering of ADS 33
Benitec Biopharma Completes Second Tranche Of Private Placement Of Shares For US$28 Million 35
Benitec Biopharma Completes Rights Offering Of Shares For US$2.7 Million 37
Benitec Biopharma Completes Private Placement Of Shares For US$7 Million 38
Benitec Biopharma Completes Second Tranche Of Private Placement Of Shares For US$7.2 Million 39
Benitec Biopharma Completes Private Placement Of Shares For US$0.2 Million 41
Benitec Biopharma Completes Private Placement Of Shares For US$0.8 Million 42
Acquisition 43
Benitec Biopharma Completes Acquisition Of Tacere Therapeutics For Up To US$1.2 Million 43
Benitec Biopharma Ltd – Key Competitors 44
Benitec Biopharma Ltd – Key Employees 45
Benitec Biopharma Ltd – Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Recent Developments 47
Financial Announcements 47
May 31, 2018: Benitec Biopharma reports financial results for the 2018 fiscal third quarter and provides operational update 47
May 31, 2018: Benitec Biopharma: Interim Report for the nine months ended March 31, 2018 49
Feb 22, 2018: Benitec Biopharma reports financial results for the 2018 fiscal second quarter and provides operational update 50
Nov 29, 2017: Benitec Biopharma reports financial results for the 2018 fiscal first quarter and provides operational update 52
May 30, 2017: Benitec Biopharma : Interim Report for the nine months ended March 31, 2017 54
Corporate Communications 55
Sep 19, 2018: Benitec Biopharma names Gregory R. Reyes as senior scientific advisor 55
Oct 23, 2017: Benitec announces resignation of Director, Dr John Chiplin 56
Oct 12, 2017: Benitec announces the appointment of a new Chairman 57
Oct 10, 2017: Benitec announces resignation of Chief Business and Operations Officer 58
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59

List of Tables
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Benitec Biopharma Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Benitec Biopharma Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Benitec Biopharma Acquires Rights to Hepbarna from Biomics 13
Axovant Sciences Enters into Research Partnership with Benitec Biopharma 14
Benitec Biopharma to Enter into Research Agreement with NantVentures 15
ReNeuron Enters into Research Agreement with Benitec Biopharma 16
Benitec Biopharma Enters Into An Agreement With Stanford University 17
Axovant Sciences Enters into Licensing Agreement with Benitec Biopharma 18
Benitec Biopharma Enters into Licensing Agreement with Nant Capital 19
Benitec Biopharma Enters into Licensing Agreement with Asklepios BioPharma 20
Benitec Biopharma Enters into Option for License Agreement with Touchlight Genetics for doggybone DNA 21
Benitec Biopharma Enters into Licensing Agreement with Circuit Therapeutics 22
Benitec Biopharma Enters Into Licensing Agreement With Regen BioPharma For ddRNAi Gene Silencing Technology 23
Benitec Biopharma Enters Into Licenising Agreement With uniQure 25
Benitec Biopharma Enters Into Licensing Agreement With Genable Technologies 26
Benitec Enters Into Licensing Agreement With Calimmune For ddRNAi Technology 27
Benitec Biopharma Enters into Licensing Agreement with 4D Molecular Therapeutics 28
Benitec Biopharma Enters Into Licensing Agreement With University of New South Wales For Tribetarna 29
Benitec Biopharma Raises USD4.7 Million in Rights Offering of Shares 30
Benitec Biopharma to Raise USD2 Million in Private Placement of American Depositary Shares 31
Benitec Biopharma Raises USD4.11 million in Private Placement of Shares 32
Benitec Biopharma Raises USD13.8 Million in Public Offering of ADS 33
Benitec Biopharma Completes Second Tranche Of Private Placement Of Shares For US$28 Million 35
Benitec Biopharma Completes Rights Offering Of Shares For US$2.7 Million 37
Benitec Biopharma Completes Private Placement Of Shares For US$7 Million 38
Benitec Biopharma Completes Second Tranche Of Private Placement Of Shares For US$7.2 Million 39
Benitec Biopharma Completes Private Placement Of Shares For US$0.2 Million 41
Benitec Biopharma Completes Private Placement Of Shares For US$0.8 Million 42
Benitec Biopharma Completes Acquisition Of Tacere Therapeutics For Up To US$1.2 Million 43
Benitec Biopharma Ltd, Key Competitors 44
Benitec Biopharma Ltd, Key Employees 45
Benitec Biopharma Ltd, Other Locations 46
Benitec Biopharma Ltd, Subsidiaries 46

List of Figures
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Benitec Biopharma Ltd, Medical Devices Deals, 2012 to YTD 2018 10

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Benitec Biopharma Ltd (BLT):製薬・医療:M&Aディール及び事業提携情報(Benitec Biopharma Ltd (BLT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆